Another medication that fails to treat COVID-19 is mild-to-moderate asthma’s fluticasone furoate, a recent study reveals.
Dr. Adrian Hernandez, executive director of the Duke Clinical Research Institute and the study’s principal investigator, stated in a Duke news release that there was no evidence of a faster time to recovery or a decrease in hospitalizations in participants who took fluticasone furoate compared to those who took a placebo.
The results come from a large, countrywide trial with approximately 5,000 participants that are currently assessing the potential advantages of using already available medications to treat mild-to-moderate COVID-19. One of three FDA-approved drugs that have been repurposed that are being evaluated against COVID-19 is fluticasone furoate.
Medication used for various medical purposes but still allowed by the US Food and Drug Administration is known as repurposed medication.
An inhaled corticosteroid called fluticasone furoate is used to treat asthma, however, it is not authorized to treat COVID-19. Corticosteroids had shown promise in treating COVID-19 in outpatients, which is why this medication was investigated. The researchers emphasized that fluticasone furoate shouldn’t be used to treat COVID-19 in light of their findings.
The study was released online on July 13 via medRxiv, which disseminates papers without peer review.